vs
Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
GEN Restaurant Group, Inc. is the larger business by last-quarter revenue ($49.7M vs $28.1M, roughly 1.8× ARS Pharmaceuticals, Inc.). GEN Restaurant Group, Inc. runs the higher net margin — -3.8% vs -147.1%, a 143.3% gap on every dollar of revenue. On growth, GEN Restaurant Group, Inc. posted the faster year-over-year revenue change (-9.0% vs -67.6%).
Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
GENK vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $49.7M | $28.1M |
| Net Profit | $-1.9M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -24.5% | -147.6% |
| Net Margin | -3.8% | -147.1% |
| Revenue YoY | -9.0% | -67.6% |
| Net Profit YoY | -821.4% | -182.8% |
| EPS (diluted) | $-0.37 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $49.7M | $28.1M | ||
| Q3 25 | $50.4M | $32.5M | ||
| Q2 25 | $55.0M | $15.7M | ||
| Q1 25 | $57.3M | $8.0M | ||
| Q4 24 | $54.7M | $86.6M | ||
| Q3 24 | $49.1M | $2.1M | ||
| Q2 24 | $53.9M | $500.0K | ||
| Q1 24 | $50.8M | $0 |
| Q4 25 | $-1.9M | $-41.3M | ||
| Q3 25 | $-566.0K | $-51.2M | ||
| Q2 25 | $-261.0K | $-44.9M | ||
| Q1 25 | $-301.0K | $-33.9M | ||
| Q4 24 | $-206.0K | $49.9M | ||
| Q3 24 | $25.0K | $-19.1M | ||
| Q2 24 | $277.0K | $-12.5M | ||
| Q1 24 | $496.0K | $-10.3M |
| Q4 25 | -24.5% | -147.6% | ||
| Q3 25 | -7.4% | -163.7% | ||
| Q2 25 | -3.4% | -302.9% | ||
| Q1 25 | -3.8% | -466.3% | ||
| Q4 24 | -2.4% | 54.5% | ||
| Q3 24 | 0.2% | -1051.6% | ||
| Q2 24 | 3.0% | -3068.0% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | -3.8% | -147.1% | ||
| Q3 25 | -1.1% | -157.4% | ||
| Q2 25 | -0.5% | -285.6% | ||
| Q1 25 | -0.5% | -425.7% | ||
| Q4 24 | -0.4% | 57.7% | ||
| Q3 24 | 0.1% | -925.0% | ||
| Q2 24 | 0.5% | -2503.2% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | $-0.37 | $-0.41 | ||
| Q3 25 | $-0.11 | $-0.52 | ||
| Q2 25 | $-0.05 | $-0.46 | ||
| Q1 25 | $-0.06 | $-0.35 | ||
| Q4 24 | $-0.05 | $0.52 | ||
| Q3 24 | $0.01 | $-0.20 | ||
| Q2 24 | $0.06 | $-0.13 | ||
| Q1 24 | $0.11 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $245.0M |
| Total DebtLower is stronger | $13.6M | $96.4M |
| Stockholders' EquityBook value | $26.5M | $114.3M |
| Total Assets | $259.9M | $327.7M |
| Debt / EquityLower = less leverage | 0.51× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $245.0M | ||
| Q3 25 | $4.8M | $288.2M | ||
| Q2 25 | $9.6M | $240.1M | ||
| Q1 25 | $15.4M | $275.7M | ||
| Q4 24 | $23.7M | $314.0M | ||
| Q3 24 | $22.1M | $204.6M | ||
| Q2 24 | $29.2M | $218.7M | ||
| Q1 24 | $28.1M | $223.6M |
| Q4 25 | $13.6M | $96.4M | ||
| Q3 25 | $10.8M | $96.2M | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $6.9M | $0 | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.7M | — |
| Q4 25 | $26.5M | $114.3M | ||
| Q3 25 | $38.1M | $147.7M | ||
| Q2 25 | $41.0M | $192.3M | ||
| Q1 25 | $42.8M | $229.0M | ||
| Q4 24 | $44.1M | $256.8M | ||
| Q3 24 | $46.5M | $201.0M | ||
| Q2 24 | $45.9M | $215.2M | ||
| Q1 24 | $40.4M | $223.9M |
| Q4 25 | $259.9M | $327.7M | ||
| Q3 25 | $245.5M | $372.8M | ||
| Q2 25 | $246.3M | $313.5M | ||
| Q1 25 | $232.4M | $327.3M | ||
| Q4 24 | $240.4M | $351.2M | ||
| Q3 24 | $225.7M | $217.6M | ||
| Q2 24 | $218.8M | $222.0M | ||
| Q1 24 | $214.5M | $227.6M |
| Q4 25 | 0.51× | 0.84× | ||
| Q3 25 | 0.28× | 0.65× | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.16× | 0.00× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-426.0K | $-43.5M |
| Free Cash FlowOCF − Capex | $-5.6M | — |
| FCF MarginFCF / Revenue | -11.3% | — |
| Capex IntensityCapex / Revenue | 10.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-426.0K | $-43.5M | ||
| Q3 25 | $-1.6M | $-47.0M | ||
| Q2 25 | $3.3M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.7M | ||
| Q4 24 | $7.3M | $42.0M | ||
| Q3 24 | $1.4M | $-14.5M | ||
| Q2 24 | $5.6M | $-7.3M | ||
| Q1 24 | $3.5M | $-6.7M |
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $-7.7M | $-47.2M | ||
| Q2 25 | $-6.3M | $-39.6M | ||
| Q1 25 | $-4.7M | $-40.8M | ||
| Q4 24 | $165.0K | $41.7M | ||
| Q3 24 | $-6.8M | $-14.6M | ||
| Q2 24 | $1.2M | $-7.3M | ||
| Q1 24 | $-586.0K | $-6.8M |
| Q4 25 | -11.3% | — | ||
| Q3 25 | -15.3% | -145.4% | ||
| Q2 25 | -11.5% | -252.2% | ||
| Q1 25 | -8.2% | -512.1% | ||
| Q4 24 | 0.3% | 48.2% | ||
| Q3 24 | -13.9% | -706.3% | ||
| Q2 24 | 2.3% | -1463.4% | ||
| Q1 24 | -1.2% | — |
| Q4 25 | 10.5% | 0.0% | ||
| Q3 25 | 12.0% | 0.6% | ||
| Q2 25 | 17.5% | 0.3% | ||
| Q1 25 | 11.9% | 1.1% | ||
| Q4 24 | 13.1% | 0.3% | ||
| Q3 24 | 16.9% | 6.8% | ||
| Q2 24 | 8.0% | 7.6% | ||
| Q1 24 | 8.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 57.96× | — | ||
| Q2 24 | 20.06× | — | ||
| Q1 24 | 7.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENK
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
